Clinical TrialMay 26, 2026, 09:32 AM
Gain Therapeutics GT-02287 Phase 1b data shows 81% GluSph reduction
AI Summary
Gain Therapeutics disclosed positive interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 for Parkinson's disease. The data, presented at the 3rd International GBA1 Meeting 2026, supports continued development of the drug, showing an 81% average reduction in CSF GluSph and a 4.8-point difference in MDS-UPDRS scores for patients with elevated baseline GluSph. Participants also reported unsolicited perceived benefits, including improved sense of smell, taste, balance, gait, and sleep.
Key Highlights
- Interim Phase 1b data for GT-02287 in Parkinson's disease supports continued development.
- 16 of 19 participants from Part 1 continued into the nine-month extension, supporting tolerability.
- CSF GluSph decreased by an average of 81% after 90 days in patients with elevated baseline levels.
- DOPA decarboxylase (DDC) levels decreased after 90 days in patients with high CSF GluSph.
- Patients with elevated GluSph showed 4.8-point better MDS-UPDRS scores after 150 days.
- MDS-UPDRS scores remained stable and durable across the overall study population after 150 days.
- Unsolicited benefits included improved smell/taste (4), balance/gait (4), and sleep (3).
Price Impact
More from GANX